AZ505: A Potent and Selective SMYD2 Inhibitor for Epigenetic Regulation Research

Executive Summary: AZ505 is a substrate-competitive, potent, and highly selective inhibitor of SMYD2, a protein lysine methyltransferase implicated in epigenetic regulation and cancer biology [APExBIO]. The compound exhibits an IC50 of 0.12 μM and a Ki of 0.3 μM, with minimal off-target activity against related methyltransferases [Min Chen et al., 2023]. Peer-reviewed evidence demonstrates AZ505’s efficacy in suppressing SMYD2-driven histone and non-histone methylation, with applications spanning gastric cancer, esophageal squamous cell carcinoma (ESCC), and renal fibrosis models. The compound is supplied by APExBIO (SKU B1255) for research use only, and is not intended for diagnostic or medical applications. Solution stability and preparation parameters are well characterized, supporting robust, reproducible workflows in epigenetic and cancer biology research.

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a protein lysine methyltransferase. It methylates histones H2B, H3, and H4 at defined lysine residues, influencing gene transcription profiles. SMYD2 also methylates non-histone substrates such as the tumor suppressor proteins p53 and retinoblastoma protein (Rb), regulating their activity and stability [Min Chen et al., 2023]. Dysregulation and overexpression of SMYD2 are associated with the progression of several cancers, including gastric cancer and ESCC, as well as fibrotic disease states such as chronic kidney disease (CKD) [AZ505 Mechanistic Article]. SMYD2 catalyzes methylation at H3K4 and H3K36 sites, impacting chromatin structure and transcriptional regulation. Epigenetic modifications, particularly histone methylation, are increasingly recognized as central to the pathogenesis of cancer and fibrosis [Min Chen et al., 2023].

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule SMYD2 inhibitor developed by APExBIO (SKU B1255). It acts as a substrate-competitive inhibitor, binding to the peptide substrate binding groove of SMYD2. This prevents methylation of histone and non-histone substrates without interfering with the methyltransferase co-factor S-adenosylmethionine (SAM) [APExBIO Product Page]. The compound exhibits a half-maximal inhibitory concentration (IC50) of 0.12 μM and an inhibition constant (Ki) of 0.3 μM, determined in biochemical assays with purified SMYD2 and peptide substrates at 25°C in Tris-HCl buffer, pH 8.0 [Min Chen et al., 2023]. AZ505 shows strong selectivity, with IC50 values greater than 83.3 μM for other methyltransferases such as SMYD3, DOT1L, and EZH2. Structural studies confirm that AZ505 binds exclusively at the substrate interface and not at the SAM-binding pocket [Epigenetics Domain Article]. This mode of inhibition allows for precise modulation of SMYD2 activity in cellular models.

Evidence & Benchmarks

• AZ505 inhibits SMYD2-mediated histone methylation with an IC50 of 0.12 μM under standard biochemical assay conditions (Min Chen et al., 2023, https://doi.org/10.1016/j.jphs.2023.07.003).
• AZ505 demonstrates minimal inhibition (IC50 > 83.3 μM) against SMYD3, DOT1L, and EZH2, indicating high selectivity (Min Chen et al., 2023, https://doi.org/10.1016/j.jphs.2023.07.003).
• In a cisplatin-induced CKD mouse model, AZ505 administration reduced renal fibrosis, inhibited epithelial-mesenchymal transition (EMT), and downregulated fibrosis-related proteins in vivo (Min Chen et al., 2023, https://doi.org/10.1016/j.jphs.2023.07.003).
• AZ505 suppressed pro-inflammatory cytokine expression (IL-6, TNF-α) and Smad3/STAT3 phosphorylation in injured renal tissue (Min Chen et al., 2023, https://doi.org/10.1016/j.jphs.2023.07.003).
• In cell-based assays, AZ505 inhibited SMYD2-driven methylation of p53 and Rb, resulting in altered cell cycle progression and apoptosis in cancer cell lines (see [Mechanistic Depth Article] for translational context).
• AZ505 remained stable and active when stored at -20°C and dissolved in DMSO, with enhanced solubility achieved by warming to 37°C and sonication (manufacturer protocol, APExBIO).

Applications, Limits & Misconceptions

AZ505 is validated for use in research models of epigenetic regulation, cancer biology, and renal fibrosis. It has shown efficacy in cellular and animal models of gastric cancer, ESCC, and CKD, where SMYD2 is overexpressed. The compound enables mechanistic studies of histone methylation pathways and the functional consequences of SMYD2 inhibition. AZ505 is not intended for diagnostic, therapeutic, or in vivo clinical applications in humans.

• Epigenetic regulation research: AZ505 allows dissection of histone methylation pathways in chromatin remodeling and gene expression studies.
• Cancer biology research: It is used to assess the impact of SMYD2 inhibition on tumor suppressor function and cell proliferation.
• Gastric cancer and ESCC: AZ505 provides a model system for studying SMYD2’s oncogenic role in gastrointestinal cancers.
• Renal fibrosis and CKD models: The compound is used to elucidate SMYD2’s involvement in fibrosis, EMT, and inflammation in kidney disease.

Common Pitfalls or Misconceptions

• AZ505 is not suitable for clinical or diagnostic use; it is for laboratory research only (APExBIO).
• The compound does not inhibit methyltransferases outside the SMYD family at relevant concentrations (IC50 > 83.3 μM for DOT1L, EZH2, etc.).
• AZ505’s efficacy is contingent on proper dissolution in DMSO and adherence to recommended storage (-20°C) and preparation (37°C warming, sonication) protocols.
• Interpretation of cellular phenotypes requires confirmation of SMYD2 dependence; off-target effects are minimal but not excluded at supraphysiological concentrations.
• AZ505 does not modulate the SAM co-factor site, making it inactive against methyltransferase mutations that alter substrate binding but preserve co-factor interaction.

Workflow Integration & Parameters

AZ505 (SKU B1255) is provided as a lyophilized solid by APExBIO. For solution preparation, dissolve the compound in DMSO to the desired concentration, warming to 37°C and sonicating if needed to enhance solubility. Store aliquots at -20°C to maintain compound integrity. Use freshly prepared solutions for cell-based assays to prevent DMSO-mediated degradation. Typical working concentrations range from 0.05 μM to 5 μM, depending on cell type and assay conditions. Confirm SMYD2 inhibition via immunoblot, ELISA, or mass spectrometry for methylation marks (e.g., H3K36me2, p53K370me) at defined timepoints. Refer to the AZ505, a potent and selective SMYD2 inhibitor product page for batch-specific details and quality control data. For additional hands-on troubleshooting and comparative performance analysis, see this guide (clarifies best practices in solution handling) and this laboratory article (provides real-world use cases and reproducibility advice). These articles complement this dossier by offering operational guidance, while the current piece focuses on validated benchmarks and mechanistic claims.

Conclusion & Outlook

AZ505 is a robust and selective chemical probe for SMYD2 inhibition, enabling high-confidence studies of histone methylation pathways in epigenetic regulation and disease models. Its substrate-competitive mechanism, nanomolar potency, and high selectivity profile underpin its utility in cancer biology and fibrosis research. As new disease models and translational applications emerge, AZ505 will remain a key tool for dissecting the molecular underpinnings of SMYD2-dependent pathology. For purchase and technical documentation, refer to the APExBIO AZ505 (B1255) product page.